Afynia (formerly AIMA Laboratories) is a Canadian FemTech company that has developed a home test for endometriosis, one of the leading causes of chronic and debilitating pelvic pain (CPP). In North America alone there are 8.5M incident cases of pelvic pain in women per year, representing a $2.1B market. The current path to a diagnosis of endometriosis is costly and unnecessarily long. It takes between 5-12 years and is characterized by multiple physician visits and failed treatments. AIMA’s flagship product will shorten the diagnostic path for endometriosis allowing women clarity, timely access to treatments, and reduced costs to patients and health care providers.
The delay in diagnosing endometriosis not only worsens chronic pelvic pain, but also amplifies emotional distress and affects many aspects of life. The uncertainty can heighten physical discomfort and emotional strain, impacting schooling, work, family dynamics, personal relationships, and overall well-being. This emphasizes the need for timely diagnosis and effective management strategies to relieve the burden of endometriosis on so many lives.
EndomiR tests for the expression levels of circulating microRNAs (miRNAs) that are differentially expressed in individuals with endometriosis versus symptomatic controls.
The EndomiR Test is for informational purposes only and should not be viewed or relied upon as any form of assurance or guarantee. The information contained herein is provided for informational purposes only, it is not intended as medical advice and is not a substitute for an assessment by a medical professional. Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.
A negative result does not definitively rule out the presence of endometriosis and should be evaluated in the context of the patient's symptoms and additional testing. This test was developed and its performance characteristics determined by Afynia. It has not been cleared or approved by the Food and Drug Administration or Health Canada. Samples will be used for the test(s) requested by your doctor and by our internal research team as part of our continuous quality improvement mandate.
